Prophylactic treatment

Tissue factor pathway inhibitor

Coagulation

Thrombin

Tissue factor

Factor X

Internal medicine

Pharmacology

Medicine

Coagulopathy

Gastroenterology

Factor IX

Platelet

Blood

Tissue factor pathway inhibitor (TFPI) inhibits coagulation initiation, and TFPI inhibition enhances the activation of factor X by tissue factor. Shapiro et al report the results of a phase 2 study of prophylactic administration of the TFPI inhibitor concizumab for bleeding prevention in hemophilia, reporting efficacy in Factor VIII and IX deficiency even in patients with inhibitors to Factor VIII or IX.

Subcutaneous concizumab prophylaxis in hemophilia A and hemophilia A/B with inhibitors: phase 2 trial results